Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Kikuchi, E; Margulis, V; Karakiewicz, PI; Roscigno, M; Mikami, S; Lotan, Y; Remzi, M; Bolenz, C; Langner, C; Weizer, A; Montorsi, F; Bensalah, K; Koppie, TM; Fernández, MI; Raman, JD; Kassouf, W; Wood, CG; Suardi, N; Oya, M; Shariat, SF.
Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma.
J Clin Oncol. 2009; 27(4):612-618
Doi: 10.1200/JCO.2008.17.2361
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Langner Cord
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To assess the association of lymphovascular invasion (LVI) with cancer recurrence and survival in a large international series of patients treated with radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC). Data were collected on 1,453 patients treated with RNU at 13 academic centers and combined into a relational database. Pathologic slides were rereviewed by genitourinary pathologists according to strict criteria. LVI was defined as presence of tumor cells within an endothelium-lined space. LVI was observed in 349 patients (24%). Proportion of LVI increased with advancing tumor stage, high tumor grade, presence of tumor necrosis, sessile tumor architecture, and presence of lymph node metastasis (all P < .001). LVI was an independent predictor of disease recurrence and survival (P < .001 for both). Addition of LVI to the base model (comprising pathologic stage, grade, and lymph node status) marginally improved its predictive accuracy for both disease recurrence and survival (1.1%, P = .03; and 1.7%, P < .001, respectively). In patients with negative lymph nodes and those in whom a lymphadenectomy was not performed (n = 1,313), addition of LVI to the base model improved the predictive accuracy of the base model for both disease recurrence and survival by 3% (P < .001 for both). In contrast, LVI was not associated with disease recurrence or survival in node-positive patients (n = 140). LVI was an independent predictor of clinical outcomes in nonmetastatic patients who underwent RNU for UTUC. Assessment of LVI may help identify patients who could benefit from multimodal therapy after RNU. After confirmation, LVI should be included in staging of UTUC.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Blood Vessels - pathology
- Endothelium, Vascular - pathology
- Humans -
- Lymph Nodes - pathology
- Lymphatic System - pathology
- Middle Aged -
- Neoplasm Invasiveness -
- Recurrence -
- Urologic Neoplasms - mortality
- Urologic Neoplasms - pathology